Stentex is the result of a unique joint venture between Medtronic, one of the world's largest medical technology companies, and the Renova Group, Russia’s leading private business group. Leveraging Medtronic technology, Stentex will manufacture a complete suite of ACS products in a state-of-the-art manufacturing and R&D facility located in Moscow.
In Russia approximately 0.5 million people die each year from coronary artery disease. And many more suffer the lasting effects of a heart attack: living with fatigue, chest pain, and shortness of breath. Stentex is here to enhance the way ACS is treated by providing access to and delivering the most technically advanced and clinically proven therapies produced in Russia, including a drug-eluting coronary stent system, a bare metal coronary stent system, semicompliant and noncompliant balloon dilatation catheters, and an aspiration catheter.
The 11,000 square meter Stentex facility will house systems for advanced manufacturing, operational processes, and quality assurance. Approximately 700 engineering, manufacturing, and business professionals will be employed in the new Stentex facility.
Stentex will significantly improve ACS treatment with state-of-the-art medical devices made in Russia that enable interventional cardiologists to restore patients to healthy lives.
Being part of an ambitious strategy to reduce ACS in Russia, the Stentex aims to make its suite of products available to every patient across Russia who needs them.